

January 4, 2018

Chair and members of the Planning and Environment Committee,

Further to the September 5, 2017 direction of council with respect to the location of potential Supervised Consumption Facilities in London,

*That the Managing Director, Planning and City Planner BE DIRECTED to examine the use definition of supervised injection sites in the Zoning By-law and how this will be distinguished from the broader Zoning By-law use "clinic";*

And Council's resolution with respect to the Opioid Crisis Working Group on September 19<sup>th</sup>, 2017,

*That the following actions be taken with respect to the use of supervised consumption sites and other harm reduction measures:*

- a) *the Opioid Crisis Working Group, comprised of the Mayor, as well as other community stakeholders, under the leadership of the Medical Officer of Health, BE ENDORSED;*
- b) *the Medical Officer of Health & CEO, Middlesex-London Health Unit BE ADVISED that the Municipal Council endorses the Health Unit's and the Opioid Crisis Working Group's further study and consultation with community stakeholders regarding the use of supervised consumption sites and other harm reduction measures; and*
- c) *the Opioid Crisis Working Group BE REQUESTED to report back to the Municipal Council with details of its relationship with other strategies and working groups, and proposed terms of reference for the Working Group that would provide for:*
  - i) *consultation with the community;*
  - ii) *exploration of a response to the current situation, including the possibility of supervised consumption sites; and,*
  - iii) *development of recommendations as to how to best address the opioid crisis in London;*

*it being understood that the Working Group will liaise with the Civic Administration in the development of the proposed terms of reference, including establishing a timeline for completion of the Working Group's mandate;*

I would like to request delegation status at the January 22, 2018 meeting of the Planning and Environment Committee to update the committee on the recent announcement from the Minister of Health for Ontario with respect to Overdose Prevention Sites as well as provide results from the public consultations on Supervised Consumption Facilities held by the Middlesex-London Health Unit in November last year.

Respectfully,



Christopher Mackie, MD, MHSc, CCFP, FRCPC  
CEO & Medical Officer of Health